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background:  Atrial fibrillation (AF) is associated with a high risk of mortality and morbidity, and commonly co-exists with heart failure. Brain 
Natriuretic Peptide (BNP) is a peptide hormone secreted in response to cardiac stress by cardiomyocytes, and BNP levels are increased in patients 
with AF. The aim of our study was to evaluate the association of BNP with adverse cardiovascular events, bleeding and mortality in patients with AF.
methods:  In a consecutive cohort of AF patients seen in a tertiary referral academic institution, plasma BNP was determined at baseline and 
related to heart failure functional class (NYHA) and EHRA score of AF-related symptoms. We recorded adverse events: stroke and thromboembolic 
events, major bleeding and mortality.
results:  We included 2556 patients, 62% male, age: 75 (IQR: 60-90) years, 80% with definite heart failure, who were followed up for 610±632 
days. Mean BNP levels were 604±823 pg/ml (median 343 pg/ml). We did observe incremental BNP levels with worsening NYHA functional class 
and EHRA score (both p<0.0001). During the follow-up, there were 226 stroke or systemic embolic events (annual rate: 5.6%), 321 major bleeding 
(annual rate: 8.2%) and 373 deaths (annual rate: 8.7%). High BNP concentrations were significantly associated with embolic events (Hazard ratio 
[HR] 1.69, 95%CI 1.13-2.55, p=0.01 in the highest versus lowest BNP quartile groups), bleeding events (HR 1.93, 95%CI 1.31-2.85; p=0.001) and 
mortality (HR 4.02, 95%CI 2.91-5.56, p<0.0001). The association remained significant after adjusting for anticoagulant use, NYHA functional class, 
EHRA score, obesity, estimated glomerular filtration rate and CHA2DS2-VASc and HAS-BLED scores.
conclusions:  In a large series not limited to anticoagulated non valvular AF patients, we found that BNP may be a novel predictor of embolic 
events, major bleedings and mortality in patients with AF. BNP may help refine clinical risk stratification in these patients.
